My colleague, David Marbaugh, originally blogged on this topic for LillyPad U.S. David frequently writes about Lilly's corporate responsibility efforts.
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to assisting where we can to make lives better.
Lilly recently donated more than 25,000 vials of urgently needed insulin to the people of Tajikistan through our ongoing partnership with Project HOPE. The donation was arranged when supplies of insulin were depleted in Tajikistan, a mountainous landlocked country in Central Asia that was formerly a Soviet Republic.
The Tajikistan's Ministry of Health (MOH) approached Project HOPE and the U.S. Department of State as a last resort to help provide insulin for several thousand patients with diabetes who were unable to locate or obtain insulin needed for survival. Project HOPE contacted Lilly, and we quickly agreed to help.
"Currently, there is not just a shortage, but there is not any insulin available in the country," said Colin Credle, regional manager of humanitarian aid for Project HOPE in Central Asia. "The medicine could not have come at a more critical time."